Also known as Lexiva
Fosamprenavir (marketed by ViiV Healthcare as fosamprenavir calcium), under the trade names Lexiva (U.S.) and Telzir (Europe) is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The FDA approved it October 20, 2003, while the EMEA approved it on July 12, 2004. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making fosamprenavir a slow-release version of amprenavir and thus reducing the number of pills required versus standard amprenavir.Source: Wikipedia
Estimated Total Cost: $848.35 for an average of 28 days supply
Patients are most commonly prescribed fosamprenavir to treat human immunodeficiency virus infection (hiv), viral hepatitis, drug abuse (cocaine), and rabies.